Roche cancer drugs continue to shine, but biosimilars are on the way

Roche HQ

Sales of Roche’s cancer drugs remain strong, giving the Swiss drugmaker a solid push in the first half of the year. And while execs acknowledge that a swarm of biosimilars will present future challenges, they said Thursday they believe they have a strategy to keep that growth alive.

The Basel-based drugmaker reported that group sales for H1 were up 5% to CHF25 billion, with the pharma division turning in CHF 19.5 billion of that total and seeing 4% growth in both in the U.S. and worldwide. It gave credit to immunology treatments Xolair and Esbriet, as well as HER2-positive breast cancer drugs Herceptin and Perjeta. The company said its previous 2016 forecast for sales growth at a low- to mid-single digits in constant currencies still holds.

In a call with journalists, executives acknowledged that from mid-year 2017, Roche’s cancer portfolio will face increased competition from biosimilars of drugs like Herceptin but said they believe that between the launches of new drugs and finding new ways to combo older drugs, Roche will be able grow its cancer drug sales “through the biosimilar erosion curve of Herceptin.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

CEO Severin Schwan said that, in fact, it is a historic time in drug development at Roche. “We are in the process of launching 5 new molecule entities within the short timeframe of only one year,” Schwan said, according to a transcript of the call. “This is really unprecedented in the history of Roche and it comes at the right time.”

He called special attention to its first immuno-oncology drug, Tecentriq. It was approved in the U.S. on May 19 on an accelerated basis based strong data in a second line bladder cancer setting. “I mean it's still early days but the CHF 19 million in a little less than a month and a half,” represents solid underlying demand for Tecentriq, the CEO said.

Adding an additional lift for the drugmaker was the fact that drug sales in China, which had slowed last year, were up 8% in the first half of 2016.

- here’s the earnings release

Related Articles:
Roche's Tecentriq bursts onto immuno-oncology scene, with Merck and BMS in its sights
Roche CEO: Despite China worries, emerging markets will continue to deliver growth
Roche looks ahead to immuno-oncology, MS to back up big-selling cancer meds

Read more on

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.